We are live on ! Find out more
ONCT

Oncternal Therapeutics, Inc. Common Stock

Delisted

ONCT was delisted on the 2nd of December, 2024.

21 hedge funds and large institutions have $7.96M invested in Oncternal Therapeutics, Inc. Common Stock in 2016 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 9 increasing their positions, 4 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

125% more repeat investments, than reductions

Existing positions increased: 9 | Existing positions reduced: 4

35% less capital invested

Capital invested by funds: $12.2M → $7.96M (-$4.2M)

49% less funds holding

Funds holding: 4121 (-20)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 20

Holders
21
Holders Change
-20
Holders Change %
-48.78%
% of All Funds
0.52%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
Increased
9
Reduced
4
Closed
20
Calls
$6K
Puts
Net Calls
+$6K
Net Calls Change
+$1K

ONCT Hedge Fund Activity: Q4 2016 in Review

21 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2016, worth a combined $7.96M — down 35% from $12.2M a quarter earlier.

Sellers outnumbered buyers: 20 funds closed out of ONCT and 0 opened new positions — a net loss of 20 holders — while 4 trimmed existing stakes and 9 added.

The largest buyer was First Horizon Advisors, adding an estimated $880K. The largest seller was BVF Inc, cutting an estimated $327K.

  • 21 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2016, down from 41 in Q3 2016.
  • Funds reported $7.96M of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2016, down 35% quarter-over-quarter.
  • 0 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2016 and 20 closed out, a net change of -20 holders.
  • The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2016 was First Horizon Advisors, an estimated $880K added.
  • The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2016 was BVF Inc, an estimated $327K sold.

Based on aggregated 13F filings for Q4 2016.